Navigation Links
Dyadic International Extends All Debt Maturity Dates
Date:10/19/2013

JUPITER, Fla., Oct. 18, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into agreements with all of its outstanding promissory note holders to extend their maturity dates to January 1, 2015.  The convertible portion of the debt, representing $6.8 million of the total $8.2 million outstanding principal, may be prepaid by Dyadic at any time in whole or in part, without penalty, after March 31, 2014 with 30 days notice.  In all other respects, the terms and conditions of these promissory notes remain unchanged and in full force and effect.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "The extension of our debt provides Dyadic with greater flexibility by allowing us the option to call the convertible debt early."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dyadic International Reports Profitable 2012 Full Year Financial Results
2. Dyadic International To Announce Third Quarter 2012 Financial Results And Host Conference Call On Thursday, November 8, 2012
3. Dyadic Netherlands To Develop Enzymes For EU-Funded Research Consortium
4. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
5. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
6. CIVCO Names Darrell Newcombe as Vice President of International Sales for Radiation Oncology
7. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. WIKA Process Solutions, Deer Park, Texas Acquires Gayesco International.
11. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical ... ("Precision Lens"), today announced the signing of a ... Precision Lens will deploy a dedicated sales team ... in the U.S., primarily focused in 13 states ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):